Investors & Partnering
Diabetes is a very serious disease – for the individual patient and as well as for society as a whole – resulting in enormous increases in worldwide healthcare spending.
In PILA PHARMA, we believe that we have discovered a new treatment that can delay or maybe even stop this pandemic – and we feel obliged to explore this.
Development of novel drugs is a lengthy and costly process with a high risk of failure but with a potential to ‘do good while doing well’.
Are you the new PILA PHARMA investor?
PILA PHARMA will open for a new investment round to finance the pivotal efficacy trials of XEN-D0501 in type 2 diabetics patients.
If you are interested in becoming an investor in PILA PHARMA, please contact us for more information here.
Are you a new PILA PHARMA partner ?
Diabetes is a complex disease and the development, registration and marketing of novel diabetes drugs requires special talent, know-how and financial muscles.
PILA PHARMA’s aim is to mature XEN-D0501 as novel oral anti-diabetic agent to a stage where it becomes attractive for partnering with the right party.
If we have not yet talked to you, or if you wish more information, please contact us here.
Current investors in PILA
PILA PHARMA is founded by and partially owned by XENIA PHARMA, Denmark. Further, ALMI Invest, Sweden has invested in the company three times, ALMI Företagspartner, Sweden has awarded an innovation loan and in June 2016 and March 2017, private investors have joined the group of PILA PHARMA investors.
ALMI Invest and ALMI Företagsparter are Swedish National investment organs, that provide consultancy, investment, and loans to Swedish companies with scalable business concepts and prospects for long-term capital growth. Through the support of their experienced investment managers, innovation consultants, capital and networks, ALMI create opportunities for businesses to grow and compete in a global market. ALMI invest from the seed phase to the expansion phase and are located across the whole of Sweden, with regional knowledge and an international perspective. The ALMI portfolio consists of 400 growth companies in many different industries. Almi Invest as well as ALMI Företagspartner are subsidiaries of the public Swedish Almi Group, Almi.se